Click on image to view larger version.

Figure 2 Comparative Analysis of Target Lesion Revascularization With Drug-Eluting Stents in Diabetic Patients From Head-to-Head Randomized Controlled Trials

Likelihood of target lesion revascularization (paclitaxel-eluting stent [PES] vs. sirolimus-eluting stent [SES]) (n = 899 diabetic patients). Size of boxes indicates relative contribution of each trial. See Table 1 for further details regarding the individual trials included. CI = confidence interval; ISAR-DIABETES = Intracoronary Stenting and Angiographic Results: Do Diabetic Patients Derive Similar Benefit from Paclitaxel-Eluting and Sirolimus-Eluting Stents trial; pc = personal communication from J. J. Goy, 2006; REALITY = Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions trial; SIRTAX = Sirolimus-eluting and Paclitaxel-eluting Stents for Coronary Revascularization trial; TAXi = A Prospective Randomized Comparison Between Paclitaxel and Sirolimus Eluting Stents in the Real World of Interventional Cardiology trial.